Subjects: CCA, TDS, FVT
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO, March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 8-11, 2024.
A live webcast of the fireside chat will be available on the Company's website at www.herontx.com in the Investor Resources section.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400
SOURCE Heron Therapeutics, Inc.
These press releases may also interest you
|
News published on and distributed by:
